Efficacy analysis on overall immunotherapy and subgroups.

S, barely significant with P = 0.05.SS, substantially significant difference at 0.01 level between immunotherapy arm and the corresponding control arm.NS, no significant difference compared to the corresponding control arm.ND, no detailed data were described for.aprogress-free survival in vaccine-adopted trials and.badverse events (grades ≥3) in four vaccine or cytokine trials [16], [21], [22], [30].Each plus (+) represents one kind of adverse event (grades ≥3) for which the immunotherapy arm was significantly greater.